ZA200902487B - Pulmonary surfactant formulations and methods for promoting mucus clearance - Google Patents

Pulmonary surfactant formulations and methods for promoting mucus clearance

Info

Publication number
ZA200902487B
ZA200902487B ZA200902487A ZA200902487A ZA200902487B ZA 200902487 B ZA200902487 B ZA 200902487B ZA 200902487 A ZA200902487 A ZA 200902487A ZA 200902487 A ZA200902487 A ZA 200902487A ZA 200902487 B ZA200902487 B ZA 200902487B
Authority
ZA
South Africa
Prior art keywords
methods
pulmonary surfactant
surfactant formulations
mucus clearance
promoting mucus
Prior art date
Application number
ZA200902487A
Other languages
English (en)
Inventor
Mark E Johnson
Robert Segal
Thomas Hofmann
Robert J Capetola
Original Assignee
Discovery Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discovery Lab Inc filed Critical Discovery Lab Inc
Publication of ZA200902487B publication Critical patent/ZA200902487B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
ZA200902487A 2006-09-19 2007-09-19 Pulmonary surfactant formulations and methods for promoting mucus clearance ZA200902487B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84599106P 2006-09-19 2006-09-19

Publications (1)

Publication Number Publication Date
ZA200902487B true ZA200902487B (en) 2010-07-28

Family

ID=38921793

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902487A ZA200902487B (en) 2006-09-19 2007-09-19 Pulmonary surfactant formulations and methods for promoting mucus clearance

Country Status (11)

Country Link
US (1) US8221772B2 (enExample)
EP (1) EP2063903A1 (enExample)
JP (1) JP2010503731A (enExample)
KR (1) KR20090060348A (enExample)
AU (1) AU2007297691B2 (enExample)
BR (1) BRPI0717177A2 (enExample)
CA (1) CA2663795A1 (enExample)
MX (1) MX2009003002A (enExample)
RU (1) RU2455021C2 (enExample)
WO (1) WO2008036293A1 (enExample)
ZA (1) ZA200902487B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
EP3165234B1 (de) 2009-07-31 2019-04-03 ethris GmbH Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
CN103052380B (zh) * 2010-08-23 2015-11-25 塔科达有限责任公司 包含治疗活性物质的湿润颗粒
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) * 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
GB201406225D0 (en) * 2014-04-07 2014-05-21 Hall Roderick L Treatment for respiratory disease
MX2017001812A (es) * 2014-08-08 2017-07-17 Shenzhen Hightide Biopharmaceutical Ltd Composiciones de formulacion liquida, aparatos de administracion de medicamentos, y metodos de preparacion y uso de los mismos.
US20190380977A1 (en) * 2016-05-23 2019-12-19 University Of Iowa Research Foundation Method of treating cystic fibrosis airway disease
AU2017298202A1 (en) * 2016-07-16 2019-02-07 Lauranell Harrison Burch Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
US11096932B2 (en) 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance
EP3621979A1 (en) 2017-05-09 2020-03-18 VIB vzw Means and methods for treating bacterial infections
JP7335263B2 (ja) * 2017-12-21 2023-08-29 キウィタス セラピューティクス，インコーポレイテッド 吸入のための界面活性剤製剤
US12427273B1 (en) 2020-05-15 2025-09-30 John E. Boyd Methods for treating respiratory distress and compositions for use in the same
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
TW202506117A (zh) 2023-06-26 2025-02-16 英商維羅納製藥Ｐｌｃ公司 顆粒組成物
KR20250153517A (ko) 2024-04-18 2025-10-27 민현홍 신생아 호흡 곤란 증후군을 앓고 있는 조산아의 폐 전달을 개선하기 위한 미세기포 함유 에어로졸
WO2025231023A1 (en) * 2024-04-29 2025-11-06 Virginia Commonwealth University Aerosol surfactant therapy (ast) for respiratory distress syndrome (rds)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659805A (en) 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US5840527A (en) * 1984-12-11 1998-11-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Recombinant alveolar surfactant protein
US4918161A (en) 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
IT1203873B (it) 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
ATE163013T1 (de) 1987-11-04 1998-02-15 Byk Gulden Lomberg Chem Fab Alveolare oberflächenaktive proteine
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US4861756A (en) 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5238920A (en) 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
DE69125750D1 (de) 1990-05-21 1997-05-28 Abbott Lab Fettsäure-Oberflächenaktives-Lungenprotein Konjate
US5272252A (en) 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
WO1993021221A1 (en) 1992-04-10 1993-10-28 Abbott Laboratories Pulmonary surfactant protein fragments
US5302481A (en) 1993-06-07 1994-04-12 Xerox Corporation Toner compositions with negative charge enhancing complexes
KR100342806B1 (ko) 1993-12-08 2002-11-29 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 신규합성펩티드,이를함유하는폐표면활성제및호흡장애증후군치료제
DE4418936A1 (de) 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
DE4434629C1 (de) 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US5925334A (en) 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US7198635B2 (en) * 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
ATE407694T1 (de) * 1998-12-22 2008-09-15 Bayer Ag Methode zur beschleunigung der schleimauflöserate
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
RU2149015C1 (ru) * 1999-07-01 2000-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения постнатальных пневмоний у новорожденных
RU2149014C1 (ru) * 1999-07-01 2000-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения острых бронхопневмоний, осложненных ателектазом
DE10006179A1 (de) * 2000-02-11 2001-08-23 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe und Behandlung von chronischen Lungenerkrankungen
US6660833B1 (en) 2000-02-29 2003-12-09 Harbor-Ucla Research And Education Institute Respiratory distress syndrome therapy with peptide analogs of human SP-B
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
PT1280520E (pt) * 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
DE60101451T2 (de) 2001-03-05 2004-10-21 Pera Ivo E Inhaliergerät zur Verteilung von in einer Kapsel enthaltenen Medikamenten in Pulverform durch die Atemwege
CA2445516C (en) 2001-04-26 2007-11-20 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
RU2213746C1 (ru) * 2002-02-15 2003-10-10 Научно-исследовательский институт физико-химической медицины Компонент, обеспечивающий поверхностно-активные свойства композиций - аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний
RU2198670C1 (ru) * 2002-02-19 2003-02-20 ООО "Биосурф" Способ получения сурфактанта из легких крупного рогатого скота
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
AU2004296206A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
CA2567334A1 (en) 2004-05-20 2005-12-08 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
ATE457736T1 (de) * 2004-08-06 2010-03-15 Nycomed Gmbh Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
AU2005280281A1 (en) 2004-08-27 2006-03-09 Discovery Laboratories, Inc. Methods, systems and devices for noninvasive pulmonary delivery
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
SI1841458T1 (sl) * 2005-01-06 2012-04-30 Discovery Lab Inc Zdravljenje s predpisanim odmerjanjem surfaktanta za zdravljenje ali preprečevanje bronhopulmonalne displazije

Also Published As

Publication number Publication date
AU2007297691A1 (en) 2008-03-27
US8221772B2 (en) 2012-07-17
RU2009114825A (ru) 2010-10-27
JP2010503731A (ja) 2010-02-04
BRPI0717177A2 (pt) 2013-10-08
WO2008036293A1 (en) 2008-03-27
MX2009003002A (es) 2009-06-01
CA2663795A1 (en) 2008-03-27
US20080199410A1 (en) 2008-08-21
AU2007297691B2 (en) 2013-12-19
EP2063903A1 (en) 2009-06-03
RU2455021C2 (ru) 2012-07-10
KR20090060348A (ko) 2009-06-11

Similar Documents

Publication Publication Date Title
ZA200902487B (en) Pulmonary surfactant formulations and methods for promoting mucus clearance
IL251562A0 (en) Methods and preparations for the designation of polyubiquitin
IL243260A0 (en) Preparations and methods for the production and use of benoemulsions
PH12008500715B1 (en) Water dispersible composition and method for preparing same
PL2578081T4 (pl) Kompozycje, sposoby i urządzenia do leczenia chorób wątroby
IL213795A (en) An immunogenic preparation containing at least two different saccharides and a compound containing the aforementioned immunogenic preparation
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
IL190885A0 (en) Immunogenic compositions and methods of use
GB0522287D0 (en) Method and compositions
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
IL191482A0 (en) Novel process and formulations
ZA200808196B (en) Azoxystrobin formulations
EP1996667A4 (en) SNOW REMOVAL AGENT AND METHOD FOR PREPARING THE SAME
GB0525314D0 (en) Method and composition
EP1824466A4 (en) COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS
ZA200608932B (en) Method and compositions for epilation
ZA200803748B (en) Nematicidal compositions and methods
IL190583A0 (en) Pth formulations and methods of use
GB0618402D0 (en) Detergent composition and method
IL196638A0 (en) Methods and compositions for treating disease
ZA200802969B (en) Composition and method
EP1920064A4 (en) COMPOSITIONS AND METHODS FOR INCREASING AMPLIFICATION EFFICIENCY
GB0524927D0 (en) Compositions and method
ZA200608935B (en) Methods and compositions for epilation
GB0718271D0 (en) Lubricant formulations and methods